计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
CP-673451是一种有效的PDGFR抑制剂,对PDGFR-α和PDGFR-β的IC50值分别为10 nM和1 nM。
CP-673451是一种ATP竞争性抑制剂,被研究用于治疗癌症.与多种其他激酶如VEGFR-1\VEGFR-2\Lck\TIE-2和EGFR相比,该物质对PDGFR-α和PDGFR-β具有高选择性.在PAE-β细胞中,CP-673451可抑制PDGFR-β,IC50值为6.4 nM.CP-673451也可在H526细胞中抑制c-kit,IC50值为1.1 μM.在大鼠C6恶性胶质瘤异种移植模型中,单次口服50 mg/kg的CP-673451可降低大于50%的PDGFR-β磷酸化4小时.此外,CP-673451可在海绵血管生成模型中抑制PDGF-BB诱导的血管生成.并且,CP-673451可在Colo205\LS174T\H460和U87MG异种移植模型中抑制肿瘤生长.该物质也可降低Colo205异种移植物的微血管密度。
Information
CP-673451 is a selective inhibitor ofPDGFRα/βwithIC50of 10 nM/1 nM in cell-free assays, exhibits >450-fold selectivity over other angiogenic receptors, has antiangiogenic and antitumor activity.
In vitro
CP 673451 is a selective inhibitor of PDGFRα/β with IC50 of 10 nM/1 nM, exhibits >450-fold selectivity over other angiogenic receptors. In glioblastoma tumors, CP-673451 (33 mg/kg) provides >50% inhibition of PDGFR-β receptor for 4 hours corresponding to an EC50 of 120 ng/mL in plasma at Cmax. In a sponge angiogenesis model, CP-673451 inhibits 70% of PDGF-BB-stimulated angiogenesis at a dose of 3 mg/kg (q.d. ×5, p.o., corresponding to 5.5 ng/mL at Cmax). CP-673451 decreases cell proliferation rate through mechanisms involving reduced phosphorylation of GSK-3α and GSK-3β. In both RD and RUCH2 cultures, CP-673451 impairs rhabdosphere-forming capacity and cell differentiation, causes increased senescence.
In vivo
CP 673451 (once-daily p.o. ?0 days dosing routinely) inhibits tumor growth (ED50 < 33 mg/kg) in a number of human tumor xenografts grown s.c. in athymic mice, including H460 human lung carcinoma, Colo205 and LS174T human colon carcinomas, and U87MG human glioblastoma multiforme. In RUCH2 xenograft-bearing mice, CP 673451 reduces tumor growth and stromal cell infiltration.
Cell Data
cell lines:
Concentrations:~3000 nM
Incubation Time:18 min
Powder Purity:≥99%